C

Caliway Biopharmaceuticals Co Ltd
TWSE:6919

Watchlist Manager
Caliway Biopharmaceuticals Co Ltd
TWSE:6919
Watchlist
Price: 1 005 TWD 0.8% Market Closed
Market Cap: 155.4B TWD

Wall Street
Price Targets

Price Targets Summary
Caliway Biopharmaceuticals Co Ltd

Wall Street analysts forecast Caliway Biopharmaceuticals Co Ltd stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for Caliway Biopharmaceuticals Co Ltd is 1 060.8 TWD with a low forecast of 1 050.4 TWD and a high forecast of 1 092 TWD.

Lowest
Price Target
1 050.4 TWD
5% Upside
Average
Price Target
1 060.8 TWD
6% Upside
Highest
Price Target
1 092 TWD
9% Upside
Caliway Biopharmaceuticals Co Ltd Competitors:
Price Targets
4577
Daito Pharmaceutical Co Ltd
5% Downside
EYPT
EyePoint Pharmaceuticals Inc
257% Upside
GLAXO
GlaxoSmithKline Pharmaceuticals Ltd
7% Downside
ABBOTINDIA
Abbott India Ltd
10% Upside
ELAN
Elanco Animal Health Inc
7% Upside
4552
JCR Pharmaceuticals Co Ltd
19% Upside
EMCURE
Emcure Pharmaceuticals Ltd
16% Upside
SDZ
Sandoz Group AG
4% Upside

Revenue
Forecast

Revenue Estimate
Caliway Biopharmaceuticals Co Ltd

For the last 4 years the compound annual growth rate for Caliway Biopharmaceuticals Co Ltd's revenue is 44%. The projected CAGR for the next 2 years is 1 065%.

44%
Past Growth
1 065%
Estimated Growth
N/A
Estimates Accuracy
N/A
Average

Operating Income
Forecast

Operating Income Estimate
Caliway Biopharmaceuticals Co Ltd

N/A
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average

Net Income
Forecast

Net Income Estimate
Caliway Biopharmaceuticals Co Ltd

N/A
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is Caliway Biopharmaceuticals Co Ltd's stock price target?
Price Target
1 060.8 TWD

According to Wall Street analysts, the average 1-year price target for Caliway Biopharmaceuticals Co Ltd is 1 060.8 TWD with a low forecast of 1 050.4 TWD and a high forecast of 1 092 TWD.

What is Caliway Biopharmaceuticals Co Ltd's Revenue forecast?
Projected CAGR
1 065%

For the last 4 years the compound annual growth rate for Caliway Biopharmaceuticals Co Ltd's revenue is 44%. The projected CAGR for the next 2 years is 1 065%.

Back to Top